The subject matter described herein relates to systems and methods for controlling fluid flow to a patient through a fluid pathway.
There are a number of patient clinical settings including in-hospital, outpatient, in-home care and emergency medical services (EMS) that require fluid administration to a patient. Standard clinical best practice is to label fluids intended to be delivered to patients to reduce the potential for errors. However, mistakes in compatibility of fluids with a particular patient, incorrect dose measurements, inappropriate sequence of medications, incorrect transfer of labeling information and other factors are a major obstacle to overcome in patient care.
In one aspect, an apparatus includes a fluid inlet, a fluid outlet, a fluid flow stop, an identification sensor, and a flow state controller. The fluid inlet is configured to couple to an outlet of a manually administrable fluid source having fluid source information encoded thereon. The fluid outlet is configured to deliver fluid from the manually administrable fluid source to a fluid line leading to a patient. The fluid flow stop is disposed between the fluid inlet and the fluid outlet that prevents fluid flow in a first state and permits fluid flow in a second state. The identification sensor to detect the fluid source information when the manually administrable fluid source is being coupled or is coupled to the fluid inlet. The flow state controller selectively causes the fluid flow stop to transition between the first state and the second state based on the fluid source information detected by the identification sensor.
The flow state controller can use a plurality of rules to determine whether to transition the current state of the fluid flow stop to the other state. Some or all of the rules can be obtained from a remote data source polled by the flow state controller. A rules engine (i.e., software and/or hardware for applying the rules, etc.) can take into account the fluid source information, flow control input data, and one or more attributes of the patient and their history, clinical circumstances, environmental factors, clinical best practices and the like. The rules engine can be configurable and programmable according to one or more of user-inputted specifications (via for example, an interface on the apparatus or via a remote computing system/interface, etc.), patient specific data, and/or medication specific data.
A fluid composition sensor can be additionally incorporated to characterize a composition of the fluid when the manually administrable fluid source is coupled to the fluid inlet. In some cases, the fluid composition sensor can be used in place of the identification sensor while in other implementations it is used in combination with the identification sensor. In either arrangement, the flow state controller can further selectively cause the fluid flow stop to transition between the first state and the second state based on the fluid composition detected by the fluid composition sensor.
The flow state controller can transmit data characterizing the fluid source information detected by the identification sensor to a remote rules engine that sends a signal indicating whether to change a current state of the fluid flow stop. The fluid source information can be indicative of a characteristic of the fluid (e.g., medication, etc.) contained therein and can include one or more of an NDC code (National Drug Code), a segment of the NDC code identifying the drug product, a segment of the NDC code identifying the drug package, a unique identifier code, a human readable alphanumeric string, a machine readable code, a name of the medication, a manufacturer of the medication, a re-packager of the medication, a distributor of the medication, a strength of the medication, a dosage form of the medication, dose instructions for the medication, administration instructions for a specific patient, medication formulation, medication package form, medication package size, medication contained volume, medication package serial number, medication lot number, and medication expiration date, fluid type, and blood type. The fluid source information can include a code or identifier used to reference a secondary data set that is characteristic of the fluid contained therein (i.e., a reference to a lookup table, a database object, a URL, etc.). The apparatus can include memory that stores the secondary data set locally and/or a remote data store can be coupled to the flow state controller that stores the secondary data set. The remote data store can form part of a medical device or medical information system.
The transition between states can be automatically initiated and executed by the flow state controller without user intervention. The transition between states can be automatically initiated and executed by the flow state controller as a result of coupling the fluid source outlet to the fluid inlet.
An interface can be included to provide audio and/or visual feedback to a user characterizing one or more of the fluid source information, volume of fluid administration, rules engine information, and/or rules engine output. The interface can provide an indication to the user when the fluid flow stop is in the first state, an indication to the user of one or more rules used by a rules engine causing a fluid flow stop state transition, and/or an indication to the user without a fluid flow stop state transition. The interface can be adjacent to the fluid inlet and/or it can be remote from the fluid inlet (e.g., a display monitor wirelessly coupled to the flow state controller, etc).
The interface can display medication administration information associated with the fluid. Such medication administration information can be stored on local memory. A communications module can be included to transmit and/or receive the medication administration information to or from a remote data source. The interface can be adjacent to or remote from the fluid inlet.
A manual override element, which when activated by a user, can cause the flow state controller to cause the fluid flow stop to transition from the first state to the second state.
A communications module can be included to transmit and/or receive data to or from a remote data source characterizing one or more of the flow control input data, fluid source, the rules or a portion of the rules, and/or the patient.
In some implementations, there can be a plurality of fluid inlets that are each configured to couple to an outlet of one of a plurality of manually administrable fluid sources each having fluid source information thereon. In these arrangements, there can be a plurality of fluid flow stops that are each coupled to the flow state controller to selectively prevent fluid flow in at least one of the plurality of fluid inlets.
The fluid flow stop can be maintained in the first state until it is determined, by using the fluid source information, to transition the fluid flow stop to the second state. The fluid flow stop can be maintained in the second state until it is determined, by using the fluid source information, to transition the fluid flow stop to the first state. The flow state controller can receive data characterizing the patient that is used, in combination with the fluid flow source information, to determine whether to transition the current state of the fluid flow stop. The data characterizing the patient can include, for example, a medication order that is used to confirm whether the fluid in the fluid source matches one or more parameters specified by the at least one medication order. The data characterizing the patient can include a patient identifier that the flow state controller uses to poll at least one remote data store using the patient identifier to obtain reference information for the flow state controller to determine whether to transition the current state of the fluid flow stop.
A fluid flow sensor can be utilized that measures how much fluid has been delivered from the fluid source into the fluid inlet. The flow state controller can cause the fluid flow stop to transition from the second state to the first state when a pre-determined volume has been delivered as measured by the fluid flow sensor. An interface can provide audio and/or visual feedback indicating how much fluid has been delivered as measured by the fluid flow sensor. The flow state controller can cause the fluid flow stop to transition from the second state to the first state when a first pre-determined volume has been delivered as measured by the fluid flow sensor, and after a pre-determined span of time, can cause the fluid flow stop to transition from the first state to the second state. The rules can utilize flow control input data information such as fluid information, patient-specific information, medical order information, clinical guideline information, contraindications, environmental factor information including time, flow control valve status, and historical information.
The identification sensor can detect the fluid source information using one or more technologies selected from a group consisting of: optical, magnetic, mechanical, conductive, switchable, infrared, switchable RFID and proximity sensors. In some cases, the identification sensor includes an optical element which detects an identifier encoded on a tip/outlet of the manually injectable medication container.
A housing can envelope at least a portion of each of the fluid inlet, the fluid outlet, the fluid flow stop, the identification sensor, and the flow state controller. Such a housing can have a compact form/shape and size that allows a user to hold the housing in a first hand while activating the manually injectable medication container in a second hand. The housing can also include a self-contained power source within the housing powering the fluid flow stop, the identification sensor, and the flow state controller and the fluid line can be an intravenous (IV) fluid line. The compact housing can, for example, be suspected from the IV fluid line.
The housing can be subdivided into reusable sub-housing and a disposable sub-housing. The reusable sub-housing can be operatively coupled to the disposable sub-housing with the reusable sub-housing being intended for use by a plurality of patients and the disposable sub-housing being intended for use by a single patient. The disposable sub-housing can contain at least the fluid inlet, fluid outlet, flow channel, and fluid flow stop. The disposable sub-housing can be part of a kit including a sterile pouch enveloping the disposable sub-housing. The disposable sub-housing can include memory for storing data that can include flow stop configuration information, flow sensor calibration information and/or a serial number or a unique identification number.
In an interrelated aspect, fluid source information of a manually administrable fluid source is detected by an identification sensor of a fluid delivery device, Thereafter, it is determined, using the detected fluid source information, whether to transition the current state of the fluid flow stop to the other state. A flow state controller of the fluid delivery device then causes a fluid flow stop to transition to the other state (e.g., open or closed) if it is determined that the fluid flow stop should transition to the other state. Otherwise, the current state of the fluid flow stop is maintained if it is not determined that the fluid flow stop should transition to the other state.
Computer program products are also described that comprise non-transitory computer readable media storing instructions, which when executed by at least one data processor of one or more computing systems, causes the at least one data processor to perform operations herein. Similarly, computer systems are also described that may include one or more data processors and a memory coupled to the one or more data processors. The memory may temporarily or permanently store instructions that cause at least one processor to perform one or more of the operations described herein. In addition, methods can be implemented by one or more data processors either within a single computing system or distributed among two or more computing systems. For example, the rules engine can be software-based or a combination of software-hardware based.
The accompanying drawings, which are incorporated in and constitute a part of this specification, show certain aspects of the subject matter disclosed herein and, together with the description, help explain some of the principles associated with the disclosed embodiments. In the drawings:
Like reference symbols in the various drawings indicate like or similar elements.
Described herein are systems and methods for controlling fluid delivery to a patient through a fluid delivery pathway. The systems and methods described herein incorporate a rules-based clinical decision support logic to drive a flow control valve within a flow pathway to determine whether the IV fluid connected to the input port is appropriate for delivery to a specific patient (consistent with medical orders, accepted delivery protocols, and/or specific patient and patient histories, etc.).
It is standard practice to query patients and place in the patient file medical record information such as blood type, known drug allergies, drugs patient is currently taking, dietary restrictions, etc. This data provides a caregiver with information regarding potential adverse reactions a particular patient may experience upon administration of fluids to be administered. In an in-hospital setting this patient-specific information typically is entered or resides in an Admission, Discharge and Transfer (ADT) system or other clinical documentation system. Clinical guidelines and best practices also support a host of non-patient-specific medical information that can be routinely taken into consideration by prescribers of IV medications/fluids such that administering clinicians can avoid inducing patient adverse events. This information can include, but is not limited to drug-drug interactions, blood type matching, appropriate drug dosing limits, impact of current vital signs on treatments, metabolic factors and/or lab results.
Fluids can be delivered according to a medical order defined by a prescribing physician. Delivery orders can specify information such as type of fluid, medication dose, frequency of dose, administration route, etc. In an in-hospital setting these orders can typically reside in a Pharmacy Information System (PIS), Blood Bank Information System (BBIS), or Operating Room Information System (ORIS). Safe delivery of medications or other fluids to patients can require clinicians to execute according to the prescribed medical orders, while simultaneously taking into consideration patient-specific health characteristics (e.g. blood type) and history (e.g. medications previously administered, allergies), drug-specific clinical guidelines, and a host of environmental circumstances such as current vital signs, time, etc.
Turning now to
The microprocessor 125 can communicate with one or more external systems 135. Communication between the system 100 described herein and the one or more external systems 135 can include wired or wireless communication methods. The external system 135 also can include, for example, a data collection system such as a personal computer or computer server running various healthcare information systems such as PIS, BBIS, ORIS, or ADT systems. Additionally, the external system 135 also can be a medical device such as an IV infusion. The system 100 can include a fluid source reader 145 coupled to the inlet 105 and configured to detect one or more information sources carried by the fluid source connected to the inlet 105. Information detected by the fluid source reader 145 can be indicative of a characteristic of the fluid contained within the fluid source container, such as type, volume, concentration, expiration, manufacturer's information regarding contents, etc. The information can be detected by the fluid source reader 145 according to a variety of methods, including but not limited to optical, magnetic, mechanical, conductive, switchable, proximity sensors, IrDA, RFID, etc. Communication systems between inlets, fluid source readers and fluid source identification systems are described in detail in U.S. Pat. Nos. 8,394,053, filed Nov. 6, 2009; 8,355,753, filed Apr. 22, 2010; and 8,385,972, filed Nov. 2, 2010, which are each incorporated by reference herein in their entirety.
The communication between the microprocessor 125 and the one or more external systems 135 can be bi-directional such that the microprocessor 125 can both receive and transmit flow control input data 140. Flow control input data 140 can include, but are not limited to, 1) information about the fluid source such as type of fluid, volume of fluid, concentration of fluid, etc.; 2) constant patient-specific information such as patient identification number, drug allergies, blood type, etc.; 3) variable patient-specific information such as patient vitals, lab results, current disease states and/or clinical diagnoses, drugs previously administered, etc.; 4) medical orders such as drug, dose, route of administration, treatment schedule, etc.; 5) clinical guidelines such as known drug-drug interactions, recommended treatment protocols, etc.; 6) environmental factors such as time of day, date, temperature, etc.; 7) valve status such as currently open (second state) or currently closed (first state); 8) historic patient information such as disease state, clinical diagnosis, dosing history, etc.; and 9) other miscellaneous information such as manual valve override, etc. Communication between the system 100 and the one or more external systems 135 is discussed in more detail below.
The systems described herein are generally small and light-weight systems that can reduce the risk of serious medical errors and deaths by controlling flow through a fluid delivery pathway. It should be appreciated that the systems described herein can be applied to any care environment where fluids are delivered to patients, including hospitals, clinics, outpatient surgery centers, doctor's offices, home health settings, EMS, ambulances, etc.
The system 100 described herein can be enclosed by a small plastic housing such that fluid inlet 105 and outlet 110 are available for external connections. The housing can enclose the fluid pathway 120, one or more flow control valves 115, and a power source 155. The housing can additionally enclose one or more of a microprocessor 125, a memory 150, a transmitter/receiver 157, a rules engine 130, and a fluid source reader 145. The housing can be a low-cost, single-patient use, sterile, disposable assembly. Alternatively, the housing can include most or all of the system components and be reusable and rechargeable. In some implementations, the reusable housing can mate with and attach to a disposable flow path 120 with the flow control valve 115, power source 155 and transmitter/receiver 157. The disposable housing can be packaged sterile and be provided in a protective pouch. Any one or more of the components of the system 100 can be included or excluded from the housing in any number of alternative implementations.
In some implementations, system 100 can be subdivided and have components distributed such that a portion reside within a disposable sub-housing and the remainder reside outside the disposable sub-housing. The disposable sub-housing can include a subset of memory 150 storing characteristics of the components within the disposable sub-housing relevant for proper operation when the disposable and reusable components are combined to form a complete system 100 (e.g. flow path characteristics, number of fluid inlets, number and arrangement of flow control valves, serial number, etc.).
As mentioned above, the system 100 can include a flow control valve 115 positioned within the flow path 120 between the inlet 105 and the outlet 110. The flow control valve 115 can be a programmable valve that can toggle between two states in response to flow state commands 122 from the configurable rules engine 130. The actual configuration of the valve 115 can vary, but generally the valve type is limited to all-on “OPEN” state or an all-off “CLOSED” state. The valve type can vary including, but not limited to, gate valves, globe valves, T valves, butterfly valves, ball valves, check valves, plug valves, pinch valves, diaphragm valves, and the like.
The flow control valve 115 is generally positioned upstream from the fluid outlet 110 and downstream from the fluid inlet 105, but the actual location of the valve 115 relative to other components of the IV set can vary.
Similarly, the fluid source reader 145 can be positioned on various segments of the flow path 120 depending on the configuration of the components in the set. In some implementations, the fluid source reader 145 can be positioned in an upstream location along the same flow path as the flow control valve 115. In some implementations, the fluid source reader 145 can be positioned along a different portion of the flow path 120 as the flow control valve 115. For example, in a “Y-site” configuration such as shown in
The microprocessor 125 can include a flow control valve software application in combination with rules engine 130 that evaluates combinations of flow control input data 140 against configurable logic for determining the proper state of the flow control valve 115 at any given time prior to or during a treatment regimen or fluid delivery protocol (see the diagram 300 of
The system 100 can be configured to operate in different operative modes. In some implementations, the system 100 operates in a normally CLOSED mode where the baseline state of the flow control valve 115 is closed (first state) and the fluid path 120 is opened during a fluid delivery and then closed again upon completion of the delivery (see
As shown in the process flow diagram 400 of
If the system 100 does not fail one or more of the safety checks, the valve, if closed, can be changed from a closed state to an open state (432). In some implementations, the system 100 can measure fluid volume in real-time during delivery of the fluid (434) and calculate the actual dose delivered and compare it to the ordered dose (436). The ordered “dose” can include a specific fluid volume (e.g. 1 liter of blood) or a quantity calculated by multiplying fluid volume by a fluid source concentration (e.g. 2 mL of 1 mg/mL concentration of morphine fluid source). Once the ordered dose is reached or the system 100 detects the fluid source is detached from the system 100, a flow state command 122 can be sent to close flow control valve 115 (440) in preparation for the next fluid administration. The administration conditions and results can be communicated to the system memory 150 and/or an external system 135 for recording (438).
In some implementations, the rules engine 130 logic can be defined such that triggering an alarm or alarm message to alert the clinician is an independent event from sending a flow control command 122 to flow control valve 115. Rules logic can generate tiered messages and/or flow state commands 122 using multiple trigger points based on the severity of a potential safety risk. For example, if the physician-ordered dose for a fluid is 100 mL, the rules engine 130 can send an message to the clinician without closing the flow control valve 115 when the dose administered reaches 105 mL of fluid. However, if dose administration continues and the cumulative dose volume reaches 110 mL of fluid, the rules engine can send a second clinician message and a flow state command 122 to close flow control.
Referring now to the process flow diagram 500 of
If no safety checks are triggered, fluid volume can be measured in real-time during administration (532). If it is determined during administration that the ordered dose was achieved or the fluid source was detached (534), then proceed to 536, if not the process 534 continues. Once such a determination is made administration results are transmitted to a recording system (internal or external) (536).
As described above, the rules engine can also trigger messages independent of flow state command 122 and transmit the data to record the condition in a memory 150 of the system 100 and/or one or more external systems 135. The valve 115 can re-open after the error condition is resolved, after a clinician manually overrides the flow control valve 115, or once the fluid source is detached. If all the safety checks are passed, a flow state command 122 can be sent to flow control valve 115 to remain open and allow fluid delivery to the patient.
It should be appreciated that the systems described herein can, but need not transmit data to an external system 135 for recording and logging data. For example, the system 100 can incorporate the intelligent flow control features of the programmable flow control valve 115 and provide user feedback (such as alarms and other alert messages) without transmitting, and/or recording the data to an external system 135.
The system 100 can be programmed with information downloaded into the system memory 150 prior to use, in real-time using on-demand connectivity with the external systems 135 or a combination of the two. In some implementations, the system 100 can be pre-programmed according to a subset of static flow control data 140 (e.g. patient blood type, known drug allergies, dose limits, etc.) prior to or upon connection to a patient's fluid line. The system can be programmed using a dockable cradle, wireless communications interface or a wired connector. In some implementations, a low-cost, non-wireless version of the system 100 can be pre-programmed with only non-patient-specific rules such as drug-drug interactions, hard dosing limits, etc. for generic use with any patient. The system 100 can be provided to a buyer including the pre-programmed non-patient-specific information or according to published clinical guidelines and standards. The non-patient-specific information can be programmed prior to clinical use by a manufacturer, care provider or by a hospital pharmacist, or other care setting based on provider-specific rules and operating procedures.
In some implementations, the system 100 can be programmed and/or communicate information in real-time to the one or more external systems 135 using a wireless transmission 157. A variety of wireless transmission hardware and protocols can be used such as RF, IrDA (infrared), Bluetooth, Zigbee, Continue, Wireless USB, Wibree, IEEE 802 relevant standards (e.g., 802.11, 802.15, or 802.16, etc.), Direct Sequence Spread Spectrum; Frequency Hopping Spread Spectrum; cellular/wireless/cordless telecommunication protocols, wireless home network communication protocols, paging network protocols, magnetic induction, satellite data communication protocols, wireless hospital or health care facility network protocols, and other methods. The data transmissions can, in some implementations, be encrypted in order to ensure patient privacy and/or to comply with various laws relating to handling of medical data. The transmitter can have such encryption capabilities or one or more additional chipsets can be incorporated within a region of the system 100 to provide such encryption.
In some implementations, the configurable rules engine 130 can run on a microprocessor 125 remote to the system 100. The commands 122 can be sent to the system 100 in a wireless or wired manner to the flow control valve 115 embedded within the system 100 instructing the flow control valve 115 to open or close.
The system 100 described herein can include one or more mechanisms configured for receiving input from a user to control operation of the system 100 and/or providing feedback to a user from the system 100. For example, the system 100 can incorporate one or more user inputs such as one or more keys, buttons, switches, dials, or touch-screens. The system 100 can incorporate one or more user feedback mechanisms such as one or more LEDs, graphical displays, sounds, speech synthesis technology or vibration mechanisms. The visual, tactile or auditory feedback can include a sequence of notifications such as volume, color, number, intensity, or other feature of the particular feedback mechanism is varied to indicate a particular state of the system 100. In some implementations, one or more of the user inputs and/or feedback mechanisms can be remote to the system 100, such as on a computing device in communication with the system 100 such as by a wired or wireless connection using the transmitter/receiver 157.
The power source 155 can include self-contained power source such as a battery, single-use or rechargeable battery, battery array or other type of power source known in the art. Where the battery is rechargeable, there can be a connector or other interface for attaching the device to an electrical outlet, docking station, portable recharger, or so forth to recharge the battery.
In some implementations, the system 100 can include an internal fluid composition sensor configured to allow the fluid composition and concentration from the fluid source to be empirically determined. The sensor can be positioned downstream of the fluid inlet 105 and upstream of control valve 115. The internal fluid composition sensor can be the sole source of fluid type detection. In some implementations, the composition sensor can be a supplement to fluid source information carried by the fluid source container and detected by a fluid source reader 145.
The system 100 can accommodate a variety of volumes and doses, including fractional doses, or multiple fluid source connections to fulfill the desired treatment protocol of a single patient medical order. For example, a physician can order a 2 mg dose of morphine for a patient. The nurse can connect one 4 mg syringe of morphine, intending to deliver half the syringe to the patient and discard the other half. In this example, the system 100 can alert the clinician that a 4 mg syringe is connected to the system 100 and the potential dose to be delivered to the patient is too high. The system 100 can also prevent overdose by sending a flow state command 122 to close the flow control valve 115 after the first 2 mg of morphine have been delivered to the patient to prevent delivery of remaining 2 mg of morphine. Alternatively, a physician can order 2 mg of morphine for a patient. The care provider can fulfill the order by first connecting a 1 mg syringe of morphine to the system 100 and delivering the full contents of the syringe to the patient and then connecting a second 1 mg syringe of morphine to the system 100 and delivering the full contents of the second syringe to the patient. In either scenario, the physician order for 2 mg have been fulfilled and the system 100 would not provide an alert or constrain fluid flow unless a further morphine syringe is coupled to the system 100.
It should be appreciated that use of the term “therapies” or “fluids” herein is not limited to a specific fluid type, therapy or medication and can include a variety of appropriate fluids. Fluids as used herein can include, but are not limited to medications, blood-based products, nutritional solutions, electrolytes, buffer solutions, lactated Ringer's solutions, sodium bicarbonate, crystalloids, colloids, saline solutions. Blood-based products can include, but are not limited to, any component of the blood for use in blood transfusions, whole blood, fresh frozen plasma, cryoprecipitate, blood substitutes, artificial blood, oxygen-carrying substitutes. Medications can include any therapeutic fluid that can be administered intravenously or another appropriate parenteral route of administration such as intra-arterial, intraosseous, intracerebral, intracardiac, subcutaneous, or intraperitoneal. Similarly, the systems described herein can use any sort of manually administered fluid source and are not limited to a specific IV fluid source type and can include syringes, IV bags, disposable medication cartridges or pouches, IV tubing, etc. It should be appreciated that the systems described herein can be used for delivery of fluids by a variety of routes of administrations. Unless otherwise specified the terms injection, administration, or delivery as they relate to introducing a fluid to a patient is not intended to be limiting to a particular route of manual administration (i.e., administration effected by a human being as opposed to a pump).
The subject matter described herein may be embodied in systems, apparatus, methods, and/or articles depending on the desired configuration. In particular, aspects of the subject matter described herein may be realized in digital electronic circuitry, integrated circuitry, specially designed ASICs (application specific integrated circuits), computer hardware, firmware, software, and/or combinations thereof. These various implementations may include implementation in one or more computer programs that are executable and/or interpretable on a programmable system including at least one programmable processor, which may be special or general purpose, coupled to receive data and instructions from, and to transmit data and instructions to, a storage system, at least one input device, and at least one output device.
These computer programs (also known as programs, software, software applications, applications, components, or code) include machine instructions for a programmable processor, and may be implemented in a high-level procedural and/or object-oriented programming language, and/or in assembly/machine language. As used herein, the term “machine-readable medium” refers to any tangible/non-transitory computer program product, apparatus and/or device (e.g., magnetic discs, optical disks, memory, Programmable Logic Devices (PLDs)) used to provide machine instructions and/or data to a programmable processor.
The implementations set forth in the foregoing description do not represent all implementations consistent with the subject matter described herein. Instead, they are merely some examples consistent with aspects related to the described subject matter. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
Although a few variations have been described in detail above, other modifications or additions are possible. In particular, further features and/or variations can be provided in addition to those set forth herein. For example, the implementations described above can be directed to various combinations and sub-combinations of the disclosed features and/or combinations and sub-combinations of several further features disclosed above. In addition, the logic flows and steps for use described herein (e.g.,
This application claims priority to U.S. Pat. App. Ser. No. 61/500,073, filed on Jun. 22, 2011 the contents of which are hereby fully incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
607941 | Mayo | Jul 1898 | A |
614703 | Delory | Nov 1898 | A |
3430625 | McLeod, Jr. | Mar 1969 | A |
4003252 | Dewath | Jan 1977 | A |
4415802 | Long | Nov 1983 | A |
4650475 | Smith et al. | Mar 1987 | A |
4684367 | Schaffer | Aug 1987 | A |
4853521 | Claeys et al. | Aug 1989 | A |
4857713 | Brown | Aug 1989 | A |
4921277 | McDonough | May 1990 | A |
4978335 | Arthur, III | Dec 1990 | A |
5011032 | Rollman | Apr 1991 | A |
5040422 | Frankenberger et al. | Aug 1991 | A |
5062774 | Kramer | Nov 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5179862 | Lynnworth | Jan 1993 | A |
5247826 | Frola et al. | Sep 1993 | A |
5279576 | Loo et al. | Jan 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5383858 | Reilly et al. | Jan 1995 | A |
5429602 | Hauser | Jul 1995 | A |
5463906 | Spani et al. | Nov 1995 | A |
5531697 | Olsen et al. | Jul 1996 | A |
5531698 | Olsen | Jul 1996 | A |
5569212 | Brown | Oct 1996 | A |
5611784 | Barresi et al. | Mar 1997 | A |
5612524 | Sant'Anselmo et al. | Mar 1997 | A |
5628309 | Brown | May 1997 | A |
5651775 | Walker et al. | Jul 1997 | A |
5692640 | Caulfield et al. | Dec 1997 | A |
5713856 | Eggers et al. | Feb 1998 | A |
5720733 | Brown | Feb 1998 | A |
5740428 | Mortimore et al. | Apr 1998 | A |
5781442 | Engleson et al. | Jul 1998 | A |
5782814 | Brown et al. | Jul 1998 | A |
5792117 | Brown | Aug 1998 | A |
5845264 | Nellhaus | Dec 1998 | A |
5873731 | Prendergast | Feb 1999 | A |
5882338 | Gray | Mar 1999 | A |
5920263 | Huttenhoff et al. | Jul 1999 | A |
5925014 | Teeple, Jr. | Jul 1999 | A |
5941846 | Duffy et al. | Aug 1999 | A |
5984901 | Sudo et al. | Nov 1999 | A |
6019745 | Gray | Feb 2000 | A |
6039251 | Holowko et al. | Mar 2000 | A |
6106498 | Friedli et al. | Aug 2000 | A |
6123686 | Olsen et al. | Sep 2000 | A |
6192945 | Ford et al. | Feb 2001 | B1 |
D438634 | Merry | Mar 2001 | S |
6249299 | Tainer | Jun 2001 | B1 |
6256037 | Callahan | Jul 2001 | B1 |
6270455 | Brown | Aug 2001 | B1 |
6277099 | Strowe et al. | Aug 2001 | B1 |
6338200 | Baxa et al. | Jan 2002 | B1 |
6341174 | Callahan et al. | Jan 2002 | B1 |
6342889 | Callahan | Jan 2002 | B1 |
6381029 | Tipirneni | Apr 2002 | B1 |
6422094 | Ganshorn | Jul 2002 | B1 |
6464667 | Kamen et al. | Oct 2002 | B1 |
6468424 | Donig et al. | Oct 2002 | B1 |
6471089 | Liff et al. | Oct 2002 | B2 |
6482185 | Hartmann | Nov 2002 | B1 |
6497680 | Holst et al. | Dec 2002 | B1 |
6519569 | White | Feb 2003 | B1 |
6579231 | Phipps | Jun 2003 | B1 |
RE38189 | Walker et al. | Jul 2003 | E |
6626355 | Sasse et al. | Sep 2003 | B2 |
6626862 | Duchon et al. | Sep 2003 | B1 |
D481121 | Evans | Oct 2003 | S |
6641562 | Peterson | Nov 2003 | B1 |
6644130 | Imai et al. | Nov 2003 | B2 |
6671563 | Engelson et al. | Dec 2003 | B1 |
D485356 | Evans | Jan 2004 | S |
6675660 | Mosier et al. | Jan 2004 | B1 |
6685227 | Merry et al. | Feb 2004 | B2 |
6685678 | Evans et al. | Feb 2004 | B2 |
6697067 | Callahan et al. | Feb 2004 | B1 |
6731989 | Engleson et al. | May 2004 | B2 |
6733495 | Bek et al. | May 2004 | B1 |
6742992 | Davis | Jun 2004 | B2 |
6790198 | White et al. | Sep 2004 | B1 |
6798533 | Tipirneni | Sep 2004 | B2 |
6825864 | Botten et al. | Nov 2004 | B2 |
6851615 | Jones | Feb 2005 | B2 |
6854338 | Khuri-Yakub et al. | Feb 2005 | B2 |
6915170 | Engleson et al. | Jul 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6985870 | Martucci et al. | Jan 2006 | B2 |
6993402 | Klass et al. | Jan 2006 | B2 |
7000485 | Ao et al. | Feb 2006 | B2 |
7017623 | Tribble et al. | Mar 2006 | B2 |
7061831 | De La Huerga | Jun 2006 | B2 |
7074205 | Duffy et al. | Jul 2006 | B1 |
7074209 | Evans et al. | Jul 2006 | B2 |
7096072 | Engleson et al. | Aug 2006 | B2 |
7103419 | Engleson et al. | Sep 2006 | B2 |
7106479 | Roy et al. | Sep 2006 | B2 |
7107106 | Engleson et al. | Sep 2006 | B2 |
7115113 | Evans et al. | Oct 2006 | B2 |
7116343 | Botten et al. | Oct 2006 | B2 |
7117041 | Engleson et al. | Oct 2006 | B2 |
7161488 | Frasch | Jan 2007 | B2 |
7171277 | Engleson et al. | Jan 2007 | B2 |
7175081 | Andreasson et al. | Feb 2007 | B2 |
7180624 | Tipirneni | Feb 2007 | B2 |
7182256 | Andreasson et al. | Feb 2007 | B2 |
7225683 | Harnett et al. | Jun 2007 | B2 |
7236936 | White et al. | Jun 2007 | B2 |
7237199 | Menhardt et al. | Jun 2007 | B1 |
7264323 | Tainer et al. | Sep 2007 | B2 |
7299981 | Hickle et al. | Nov 2007 | B2 |
7319540 | Tipirneni | Jan 2008 | B2 |
7347841 | Elhadad et al. | Mar 2008 | B2 |
7358505 | Woodworth et al. | Apr 2008 | B2 |
7360448 | Maginnis et al. | Apr 2008 | B2 |
7364067 | Steusloff et al. | Apr 2008 | B2 |
7370797 | Sullivan et al. | May 2008 | B1 |
7375737 | Botten et al. | May 2008 | B2 |
7384410 | Eggers et al. | Jun 2008 | B2 |
7442181 | Schubert et al. | Oct 2008 | B2 |
7469598 | Shkarlet et al. | Dec 2008 | B2 |
7469599 | Froehlich et al. | Dec 2008 | B2 |
7470266 | Massengale et al. | Dec 2008 | B2 |
7483756 | Engleson et al. | Jan 2009 | B2 |
D588200 | Langan et al. | Mar 2009 | S |
7534239 | Schneider et al. | May 2009 | B1 |
D593613 | Langan et al. | Jun 2009 | S |
D595361 | Langan et al. | Jun 2009 | S |
7559483 | Hickle et al. | Jul 2009 | B2 |
7564579 | Tipirneni | Jul 2009 | B2 |
D597608 | Langan et al. | Aug 2009 | S |
D602534 | Langan et al. | Oct 2009 | S |
7614545 | Christoffersen et al. | Nov 2009 | B2 |
7617739 | Dam | Nov 2009 | B1 |
D605228 | Langan et al. | Dec 2009 | S |
D605229 | Langan et al. | Dec 2009 | S |
D605230 | Langan et al. | Dec 2009 | S |
7645258 | White et al. | Jan 2010 | B2 |
7673527 | Ehring et al. | Mar 2010 | B2 |
7694565 | Koerdt et al. | Apr 2010 | B2 |
7703336 | Genosar | Apr 2010 | B2 |
7704231 | Pongpairochana et al. | Apr 2010 | B2 |
7722083 | McCarthy et al. | May 2010 | B2 |
7727196 | Neer | Jun 2010 | B2 |
7753880 | Malackowski | Jul 2010 | B2 |
7753891 | Tennican et al. | Jul 2010 | B2 |
7756724 | Gropper et al. | Jul 2010 | B2 |
7763006 | Tennican | Jul 2010 | B2 |
D621879 | Langan et al. | Aug 2010 | S |
D621880 | Langan et al. | Aug 2010 | S |
7771385 | Eggers et al. | Aug 2010 | B2 |
D624595 | Langan et al. | Sep 2010 | S |
D624596 | Langan et al. | Sep 2010 | S |
7799010 | Tennican | Sep 2010 | B2 |
7813939 | Clements et al. | Oct 2010 | B2 |
7815123 | Conner et al. | Oct 2010 | B2 |
7815605 | Souter | Oct 2010 | B2 |
7819838 | Ziegler et al. | Oct 2010 | B2 |
7822096 | Kuksenkov | Oct 2010 | B2 |
7834816 | Marino et al. | Nov 2010 | B2 |
7859473 | Gibson | Dec 2010 | B2 |
D633151 | Langan et al. | Feb 2011 | S |
7887513 | Nemoto et al. | Feb 2011 | B2 |
D634367 | Langan et al. | Mar 2011 | S |
D634368 | Langan et al. | Mar 2011 | S |
D634369 | Langan et al. | Mar 2011 | S |
7905861 | Rhinehart et al. | Mar 2011 | B2 |
7918830 | Langan et al. | Apr 2011 | B2 |
7922073 | de la Huerga | Apr 2011 | B2 |
7927313 | Stewart et al. | Apr 2011 | B2 |
7933780 | De La Huerga | Apr 2011 | B2 |
7941949 | Cloninger | May 2011 | B2 |
D639861 | Langan et al. | Jun 2011 | S |
D639862 | Langan et al. | Jun 2011 | S |
D639863 | Langan et al. | Jun 2011 | S |
7967778 | Nemoto et al. | Jun 2011 | B2 |
D641421 | Langan et al. | Jul 2011 | S |
D641422 | Langan et al. | Jul 2011 | S |
7976508 | Hoag | Jul 2011 | B2 |
D643468 | Langan et al. | Aug 2011 | S |
D643469 | Langan et al. | Aug 2011 | S |
D643470 | Langan et al. | Aug 2011 | S |
D643471 | Langan et al. | Aug 2011 | S |
D643472 | Langan et al. | Aug 2011 | S |
7991627 | Hutchinson et al. | Aug 2011 | B2 |
D645094 | Langan et al. | Sep 2011 | S |
8031347 | Edwards et al. | Oct 2011 | B2 |
8035517 | Gibson | Oct 2011 | B2 |
D649196 | Langan et al. | Nov 2011 | S |
8059297 | Tipirneni | Nov 2011 | B2 |
8063925 | Tainer et al. | Nov 2011 | B2 |
8065924 | Ziegler et al. | Nov 2011 | B2 |
8069060 | Tipirneni | Nov 2011 | B2 |
8111159 | Andreasson et al. | Feb 2012 | B2 |
8133178 | Brauker et al. | Mar 2012 | B2 |
8140349 | Hanson et al. | Mar 2012 | B2 |
8151835 | Khan et al. | Apr 2012 | B2 |
8235938 | Eggers et al. | Aug 2012 | B2 |
8240550 | Steusloff et al. | Aug 2012 | B2 |
8303547 | Brown | Nov 2012 | B2 |
8328082 | Bochenko et al. | Dec 2012 | B1 |
8355753 | Bochenko et al. | Jan 2013 | B2 |
8385972 | Bochenko et al. | Feb 2013 | B2 |
8394053 | Bochenko et al. | Mar 2013 | B2 |
8480834 | Rice et al. | Jul 2013 | B2 |
8505809 | Steusloff et al. | Aug 2013 | B2 |
8606596 | Bochenko et al. | Dec 2013 | B1 |
8636202 | Keefe et al. | Jan 2014 | B2 |
8639521 | Eggers et al. | Jan 2014 | B2 |
8639525 | Levine et al. | Jan 2014 | B2 |
8645154 | Eggers et al. | Feb 2014 | B2 |
8702674 | Bochenko | Apr 2014 | B2 |
8752088 | Harvey et al. | Jun 2014 | B1 |
20010020148 | Sasse et al. | Sep 2001 | A1 |
20010049608 | Hochman | Dec 2001 | A1 |
20010056258 | Evans | Dec 2001 | A1 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20020077852 | Ford et al. | Jun 2002 | A1 |
20020088131 | Baxa et al. | Jul 2002 | A1 |
20020098598 | Coffen et al. | Jul 2002 | A1 |
20020099334 | Hanson et al. | Jul 2002 | A1 |
20020177811 | Reilly et al. | Nov 2002 | A1 |
20020188259 | Hickle et al. | Dec 2002 | A1 |
20030012701 | Sangha et al. | Jan 2003 | A1 |
20030052787 | Zerhusen et al. | Mar 2003 | A1 |
20030055685 | Cobb et al. | Mar 2003 | A1 |
20030065537 | Evans | Apr 2003 | A1 |
20030088238 | Poulsen et al. | May 2003 | A1 |
20030135388 | Martucci et al. | Jul 2003 | A1 |
20030139701 | White et al. | Jul 2003 | A1 |
20030139706 | Gray | Jul 2003 | A1 |
20030140929 | Wilkes et al. | Jul 2003 | A1 |
20030141981 | Bui et al. | Jul 2003 | A1 |
20030160698 | Andreasson et al. | Aug 2003 | A1 |
20030164401 | Andreasson et al. | Sep 2003 | A1 |
20030174326 | Rzasa et al. | Sep 2003 | A1 |
20040051368 | Caputo et al. | Mar 2004 | A1 |
20040082918 | Evans et al. | Apr 2004 | A1 |
20040092885 | Duchon et al. | May 2004 | A1 |
20040103951 | Osborne et al. | Jun 2004 | A1 |
20040104271 | Martucci et al. | Jun 2004 | A1 |
20040105115 | Edwards et al. | Jun 2004 | A1 |
20040179051 | Tainer et al. | Sep 2004 | A1 |
20040179132 | Fujino et al. | Sep 2004 | A1 |
20040186437 | Frenette et al. | Sep 2004 | A1 |
20040193453 | Butterfield et al. | Sep 2004 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040212834 | Edwards et al. | Oct 2004 | A1 |
20040238631 | Andreasson et al. | Dec 2004 | A1 |
20050055242 | Bello et al. | Mar 2005 | A1 |
20050059926 | Sage, Jr. et al. | Mar 2005 | A1 |
20050070978 | Bek et al. | Mar 2005 | A1 |
20050088306 | Andreasson et al. | Apr 2005 | A1 |
20050101905 | Merry | May 2005 | A1 |
20050106225 | Massengale et al. | May 2005 | A1 |
20050107923 | Vanderveen | May 2005 | A1 |
20050118048 | Traxinger | Jun 2005 | A1 |
20050151652 | Frasch | Jul 2005 | A1 |
20050151823 | Botten et al. | Jul 2005 | A1 |
20050154368 | Lim et al. | Jul 2005 | A1 |
20050165559 | Nelson | Jul 2005 | A1 |
20050182358 | Veit et al. | Aug 2005 | A1 |
20050189252 | Naylor | Sep 2005 | A1 |
20050277873 | Stewart et al. | Dec 2005 | A1 |
20050277890 | Stewart et al. | Dec 2005 | A1 |
20060032918 | Andreasson et al. | Feb 2006 | A1 |
20060065713 | Kingery | Mar 2006 | A1 |
20060079767 | Gibbs et al. | Apr 2006 | A1 |
20060079843 | Brooks et al. | Apr 2006 | A1 |
20060102503 | Elhadad et al. | May 2006 | A1 |
20060116639 | Russell | Jun 2006 | A1 |
20060122577 | Poulsen et al. | Jun 2006 | A1 |
20060143051 | Eggers et al. | Jun 2006 | A1 |
20060144942 | Evans et al. | Jul 2006 | A1 |
20060178617 | Adams et al. | Aug 2006 | A1 |
20060190302 | Eggers et al. | Aug 2006 | A1 |
20060206356 | Vanderveen | Sep 2006 | A1 |
20060224125 | Simpson et al. | Oct 2006 | A1 |
20060226089 | Robinson et al. | Oct 2006 | A1 |
20060229551 | Martinez et al. | Oct 2006 | A1 |
20060253346 | Gomez | Nov 2006 | A1 |
20060258985 | Russell | Nov 2006 | A1 |
20060265186 | Holland et al. | Nov 2006 | A1 |
20060270997 | Lim et al. | Nov 2006 | A1 |
20060287887 | Hutchinson et al. | Dec 2006 | A1 |
20070008399 | Botten et al. | Jan 2007 | A1 |
20070043335 | Olsen et al. | Feb 2007 | A1 |
20070060874 | Nesbitt et al. | Mar 2007 | A1 |
20070100316 | Traxinger | May 2007 | A1 |
20070134044 | Colbrunn et al. | Jun 2007 | A1 |
20070135765 | Miller et al. | Jun 2007 | A1 |
20070136218 | Bauer et al. | Jun 2007 | A1 |
20070166198 | Sangha et al. | Jul 2007 | A1 |
20070167919 | Nemoto et al. | Jul 2007 | A1 |
20070179448 | Lim et al. | Aug 2007 | A1 |
20070186923 | Poutiatine et al. | Aug 2007 | A1 |
20070187475 | MacLeod | Aug 2007 | A1 |
20070191787 | Lim et al. | Aug 2007 | A1 |
20070255199 | Dewey | Nov 2007 | A1 |
20070279625 | Rzasa et al. | Dec 2007 | A1 |
20070280710 | Tainer et al. | Dec 2007 | A1 |
20070293830 | Martin | Dec 2007 | A1 |
20070299421 | Gibson | Dec 2007 | A1 |
20080045930 | Makin et al. | Feb 2008 | A1 |
20080051937 | Khan et al. | Feb 2008 | A1 |
20080061153 | Hickle et al. | Mar 2008 | A1 |
20080065016 | Peterson et al. | Mar 2008 | A1 |
20080071219 | Rhinehart et al. | Mar 2008 | A1 |
20080118141 | Sommer et al. | May 2008 | A1 |
20080125724 | Monroe | May 2008 | A1 |
20080191013 | Liberatore | Aug 2008 | A1 |
20080208042 | Ortenzi et al. | Aug 2008 | A1 |
20080234630 | Iddan et al. | Sep 2008 | A1 |
20080243054 | Mollstam et al. | Oct 2008 | A1 |
20080243088 | Evans | Oct 2008 | A1 |
20080255523 | Grinberg | Oct 2008 | A1 |
20080287889 | Sharvit | Nov 2008 | A1 |
20080294108 | Briones et al. | Nov 2008 | A1 |
20080306439 | Nelson et al. | Dec 2008 | A1 |
20090018494 | Nemoto et al. | Jan 2009 | A1 |
20090030730 | Dullemen et al. | Jan 2009 | A1 |
20090036846 | Dacquay et al. | Feb 2009 | A1 |
20090043253 | Podaima | Feb 2009 | A1 |
20090069714 | Eichmann et al. | Mar 2009 | A1 |
20090069743 | Krishnamoorthy et al. | Mar 2009 | A1 |
20090085768 | Patel et al. | Apr 2009 | A1 |
20090112178 | Behzadi | Apr 2009 | A1 |
20090112333 | Sahai | Apr 2009 | A1 |
20090113996 | Wang | May 2009 | A1 |
20090126483 | Blendinger et al. | May 2009 | A1 |
20090126866 | Stenner et al. | May 2009 | A1 |
20090137956 | Souter | May 2009 | A1 |
20090143673 | Drost et al. | Jun 2009 | A1 |
20090149744 | Nemoto et al. | Jun 2009 | A1 |
20090156931 | Nemoto et al. | Jun 2009 | A1 |
20090156985 | Hottmann | Jun 2009 | A1 |
20090157008 | Vitral | Jun 2009 | A1 |
20090159654 | Grimard | Jun 2009 | A1 |
20090200185 | Follman et al. | Aug 2009 | A1 |
20090209911 | Cabus | Aug 2009 | A1 |
20090259176 | Yairi | Oct 2009 | A1 |
20090288497 | Ziegler et al. | Nov 2009 | A1 |
20090294521 | de la Huerga | Dec 2009 | A1 |
20090296540 | Gilbert et al. | Dec 2009 | A1 |
20090306620 | Thilly et al. | Dec 2009 | A1 |
20090312635 | Shimchuk et al. | Dec 2009 | A1 |
20100022953 | Bochenko et al. | Jan 2010 | A1 |
20100022987 | Bochenko et al. | Jan 2010 | A1 |
20100036310 | Hillman | Feb 2010 | A1 |
20100036313 | Shener et al. | Feb 2010 | A1 |
20100065633 | Nelson et al. | Mar 2010 | A1 |
20100065643 | Leyvraz et al. | Mar 2010 | A1 |
20100076310 | Wenderow et al. | Mar 2010 | A1 |
20100095782 | Ferencz et al. | Apr 2010 | A1 |
20100114951 | Bauman et al. | May 2010 | A1 |
20100145165 | Merry | Jun 2010 | A1 |
20100152562 | Goodnow et al. | Jun 2010 | A1 |
20100153136 | Whittacre et al. | Jun 2010 | A1 |
20100164727 | Bazargan | Jul 2010 | A1 |
20100174266 | Estes | Jul 2010 | A1 |
20100179417 | Russo | Jul 2010 | A1 |
20100204659 | Bochenko et al. | Aug 2010 | A1 |
20100262002 | Martz | Oct 2010 | A1 |
20100280486 | Khair et al. | Nov 2010 | A1 |
20100286599 | Ziegler et al. | Nov 2010 | A1 |
20100305499 | Matsiev et al. | Dec 2010 | A1 |
20110009800 | Dam et al. | Jan 2011 | A1 |
20110009817 | Bennett et al. | Jan 2011 | A1 |
20110028937 | Powers et al. | Feb 2011 | A1 |
20110060198 | Bennett et al. | Mar 2011 | A1 |
20110093279 | Levine et al. | Apr 2011 | A1 |
20110111794 | Bochenko et al. | May 2011 | A1 |
20110112473 | Bochenko et al. | May 2011 | A1 |
20110112474 | Bochenko et al. | May 2011 | A1 |
20110137288 | Tallarida et al. | Jun 2011 | A1 |
20110152824 | DiPerna et al. | Jun 2011 | A1 |
20110152825 | Marggi | Jun 2011 | A1 |
20110152834 | Langan et al. | Jun 2011 | A1 |
20110160655 | Hanson et al. | Jun 2011 | A1 |
20110161112 | Keefe et al. | Jun 2011 | A1 |
20110166511 | Sharvit et al. | Jul 2011 | A1 |
20110176490 | Mehta et al. | Jul 2011 | A1 |
20110185821 | Genosar | Aug 2011 | A1 |
20110220713 | Cloninger | Sep 2011 | A1 |
20110224649 | Duane et al. | Sep 2011 | A1 |
20110259954 | Bartz et al. | Oct 2011 | A1 |
20110264069 | Bochenko | Oct 2011 | A1 |
20110295191 | Injev | Dec 2011 | A1 |
20110313349 | Krulevitch et al. | Dec 2011 | A1 |
20110315611 | Fulkerson et al. | Dec 2011 | A1 |
20120004542 | Nemoto et al. | Jan 2012 | A1 |
20120004602 | Hanson et al. | Jan 2012 | A1 |
20120004637 | Krulevitch et al. | Jan 2012 | A1 |
20120006127 | Nielsen | Jan 2012 | A1 |
20120022458 | Oh et al. | Jan 2012 | A1 |
20120035535 | Johnson et al. | Feb 2012 | A1 |
20120037266 | Bochenko | Feb 2012 | A1 |
20120041355 | Edman et al. | Feb 2012 | A1 |
20120046295 | Charrier et al. | Feb 2012 | A1 |
20120065617 | Matsiev et al. | Mar 2012 | A1 |
20120073673 | Kameyama | Mar 2012 | A1 |
20120222468 | Nelson et al. | Sep 2012 | A1 |
20120226446 | Nelson et al. | Sep 2012 | A1 |
20120226447 | Nelson et al. | Sep 2012 | A1 |
20120287431 | Matsiev et al. | Nov 2012 | A1 |
20120323208 | Bochenko et al. | Dec 2012 | A1 |
20120325330 | Prince et al. | Dec 2012 | A1 |
20130018356 | Prince et al. | Jan 2013 | A1 |
20130105568 | Jablonski et al. | May 2013 | A1 |
20130135388 | Samoto et al. | May 2013 | A1 |
20130181046 | Fedorko et al. | Jul 2013 | A1 |
20130204227 | Bochenko et al. | Aug 2013 | A1 |
20130225945 | Prince et al. | Aug 2013 | A1 |
20130226137 | Brown | Aug 2013 | A1 |
20130327822 | Keefe et al. | Dec 2013 | A1 |
20140039383 | Dobbles et al. | Feb 2014 | A1 |
20140060729 | Srnka et al. | Mar 2014 | A1 |
20140142975 | Keefe et al. | May 2014 | A1 |
20150204705 | Forster et al. | Jul 2015 | A1 |
20150211904 | Forster | Jul 2015 | A1 |
Number | Date | Country |
---|---|---|
101732778 | Jun 2010 | CN |
4137837 | Oct 1992 | DE |
29617777 | Dec 1996 | DE |
1944709 | Jul 2008 | EP |
1980974 | Oct 2008 | EP |
2135630 | Dec 2009 | EP |
2183046 | May 1987 | GB |
2504288 | Jan 2014 | GB |
2504295 | Jan 2014 | GB |
2504297 | Jan 2014 | GB |
5317421 | Dec 1993 | JP |
2008517646 | May 2008 | JP |
201266004 | Apr 2012 | JP |
1020090025392 | Mar 2009 | KR |
03063932 | Aug 2003 | WO |
2009114115 | Sep 2009 | WO |
2010144482 | Dec 2010 | WO |
2011126485 | Oct 2011 | WO |
2012034084 | Mar 2012 | WO |
2012126744 | Sep 2012 | WO |
2013096713 | Jun 2013 | WO |
2014016311 | Jan 2014 | WO |
2014016315 | Jan 2014 | WO |
2014016316 | Jan 2014 | WO |
Entry |
---|
U.S. Appl. No. 12/614,276, filed Nov. 6, 2009, 2011-0112473. |
U.S. Appl. No. 12/765,707, filed Apr. 22, 2010, 2011-0111794. |
U.S. Appl. No. 12/768,509, filed Apr. 27, 2010, 2011-0264069. |
U.S. Appl. No. 12/938,300, filed Nov. 2, 2010, 2011-0112474. |
U.S. Appl. No. 13/149,782, filed May 31, 2011. |
U.S. Appl. No. 13/170,073, filed Jun. 27, 2011. |
U.S. Appl. No. 13/282,255, filed Oct. 26, 2011, 2012-0037266. |
U.S. Appl. No. 13/524,736, filed Jun. 15, 2012. |
U.S. Appl. No. 13/549,278, filed Jul. 13, 2012. |
U.S. Appl. No. 61/551,916, filed Oct. 26, 2011. |
Google Scholar Search [Jul. 21, 2014]. |
U.S. Appl. No. 13/524,736, filed Jun. 15, 2012, 2012-0323208. |
U.S. Appl. No. 13/549,278, filed Jul. 13, 2012, 2013-0018356. |
U.S. Appl. No. 13/689,729, filed Nov. 29, 2012, 2014-0066880. |
U.S. Appl. No. 13/777,831, filed Feb. 26, 2013, 2013-0225945. |
U.S. Appl. No. 13/777,964, filed Feb. 26, 2013, 2013-0204227. |
U.S. Appl. No. 13/802,231, filed Mar. 13, 2013, 2014-0276213. |
U.S. Appl. No. 13/671,752, filed Nov. 8, 2012. |
International Search Report dated Aug. 2, 2011 for corresponding PCT Application No. PCT/US2010/055322. |
Number | Date | Country | |
---|---|---|---|
20120325330 A1 | Dec 2012 | US |
Number | Date | Country | |
---|---|---|---|
61500073 | Jun 2011 | US |